Research ArticleOriginal Article

Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients

Xingsheng Hu, Dongyong Yang, Yalun Li, Li Li, Yan Wang, Peng Chen, Song Xu, Xingxiang Pu, Wei Zhu, Pengbo Deng, Junyi Ye, Hanhan Zhang, Analyn Lizaso, Hao Liu, Xinru Mao, Hai Huang, Qian Chu and Chengping Hu
Cancer Biology & Medicine August 2019, 16 (3) 556-564; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0506

References

  1. 1.↵
    2. Daly MB,
    3. Axilbund JE,
    4. Buys S,
    5. Crawford B,
    6. Farrell CD,
    7. Friedman S, et al.
    Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010; 8: 562–94.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    2. Wu XH,
    3. Wu LY,
    4. Kong BH,
    5. Liu JH,
    6. Yin RT,
    7. Wen H, et al.
    The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. Int J Gynecol Cancer. 2017; 27: 1650–7.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    2. Petrucelli N,
    3. Daly MB,
    4. Feldman GL.
    Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010; 12: 245–59.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Phelan CM,
    3. Iqbal J,
    4. Lynch HT,
    5. Lubinski J,
    6. Gronwald J,
    7. Moller P, et al.
    Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014; 110: 530–4.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Sopik V,
    3. Phelan C,
    4. Cybulski C,
    5. Narod SA.
    BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet. 2015; 87: 411–8.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Wang YF,
    3. McKay JD,
    4. Rafnar T,
    5. Wang ZM,
    6. Timofeeva MN,
    7. Broderick P, et al.
    Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014; 46: 736–41.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Nat Cancer Inst. 1999; 91: 1310–6.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Stadler ZK,
    3. Salo-Mullen E,
    4. Patil SM,
    5. Pietanza MC,
    6. Vijai J,
    7. Saloustros E, et al.
    Prevalence of BRCA1 and BRCA2 mutations in ashkenazi jewish families with breast and pancreatic cancer. Cancer. 2012; 118: 493–9.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Cavanagh H,
    3. Rogers KMA.
    The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 2015; 13: 16.
    OpenUrlCrossRef
  10. 10.↵
    2. Lord CJ,
    3. Ashworth A.
    Parp inhibitors: synthetic lethality in the clinic. Science. 2017; 355: 1152–8.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Bryant HE,
    3. Schultz N,
    4. Thomas HD,
    5. Parker KM,
    6. Flower D,
    7. Lopez E, et al.
    Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434: 913–7.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Farmer H,
    3. McCabe N,
    4. Lord CJ,
    5. Tutt ANJ,
    6. Johnson DA,
    7. Richardson TB, et al.
    Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434: 917–21.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Tutt A,
    3. Robson M,
    4. Garber JE,
    5. Domchek S,
    6. Audeh MW,
    7. Weitzel JN, et al.
    Phase II trial of the oral parp inhibitor olaparib in brca-deficient advanced breast cancer. J Clin Oncol. 2009; 27: CRA501.
    OpenUrl
  14. 14.↵
    2. Fong PC,
    3. Boss DS,
    4. Yap TA,
    5. Tutt A,
    6. Wu P,
    7. Mergui-Roelvink M, et al.
    Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361: 123–34.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. O'Cearbhaill RE.
    Using parp inhibitors in advanced ovarian cancer. Oncology. 2018; 32: 339–43.
    OpenUrl
  16. 16.↵
    2. Tassone P,
    3. Tagliaferri P,
    4. Perricelli A,
    5. Blotta S,
    6. Quaresima B,
    7. Martelli ML, et al.
    BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003; 88: 1285–91.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    2. Hu XC,
    3. Zhang J,
    4. Xu BH,
    5. Cai L,
    6. Ragaz J,
    7. Wang ZH, et al.
    Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015; 16: 436–46.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Tan DSP,
    3. Yap TA,
    4. Hutka M,
    5. Roxburgh P,
    6. Ang J,
    7. Banerjee S, et al.
    Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer. 2013; 49: 1246–53.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Hung RJ,
    3. McKay JD,
    4. Gaborieau V,
    5. Boffetta P,
    6. Hashibe M,
    7. Zaridze D, et al.
    A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008; 452: 633–7.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.
    2. McKay JD,
    3. Hung RJ,
    4. Gaborieau V,
    5. Boffetta P,
    6. Chabrier A,
    7. Byrnes G, et al.
    Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008; 40: 1404–6.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Wang YF,
    3. Broderick P,
    4. Webb E,
    5. Wu XF,
    6. Vijayakrishnan J,
    7. Matakidou A, et al.
    Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008; 40: 1407–9.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    2. Egawa C,
    3. Miyoshi Y,
    4. Takamura Y,
    5. Taguchi T,
    6. Tamaki Y,
    7. Noguchi S.
    Decreased expression of BRCA2 mrna predicts favorable response to docetaxel in breast cancer. Int J Cancer. 2001; 95: 255–9.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    2. Ostrander EA,
    3. Udler MS.
    The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1843–8.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    2. Risbridger GP,
    3. Taylor RA,
    4. Clouston D,
    5. Sliwinski A,
    6. Thorne H,
    7. Hunter S, et al.
    Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol. 2015; 67: 496–503.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Taylor RA,
    3. Fraser M,
    4. Livingstone J,
    5. Espiritu SMG,
    6. Thorne H,
    7. Huang V, et al.
    Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun. 2017; 8: 13671.
    OpenUrlCrossRef
  26. 26.↵
    2. Alsop K,
    3. Fereday S,
    4. Meldrum C,
    5. deFazio A,
    6. Emmanuel C,
    7. George J, et al.
    BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the australian ovarian cancer study group. J Clin Oncol. 2012; 30: 2654–63.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Moschetta M,
    3. George A,
    4. Kaye SB,
    5. Banerjee S.
    BRCA somatic mutations and epigenetic brca modifications in serous ovarian cancer. Ann Oncol. 2016; 27: 1449–55.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Schiller JH,
    3. Harrington D,
    4. Belani CP,
    5. Langer C,
    6. Sandler A,
    7. Krook J, et al.
    Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92–8.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    2. Donner I,
    3. Katainen R,
    4. Sipila LJ,
    5. Aavikko M,
    6. Pukkala E,
    7. Aaltonen LA.
    Germline mutations in young non-smoking women with lung adenocarcinoma. Lung Cancer. 2018; 122: 76–82.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Subjects

Keywords